New drug aims to slash fractures in kids with brittle bones
NCT ID NCT06636071
First seen Nov 01, 2025 · Last updated May 24, 2026 · Updated 27 times
Summary
This study tests a drug called setrusumab in Japanese children with osteogenesis imperfecta (brittle bone disease) types I, III, or IV. The goal is to see if it lowers the number of bone fractures, including spine fractures. Participants must have had at least one fracture in the past year and have a confirmed genetic cause.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OSTEOGENESIS IMPERFECTA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Keio University Hospital
Tokyo, Japan
-
Osaka Metropolitan University Hospital
Osaka, Japan
-
Osaka University Hospital
Osaka, Japan
Conditions
Explore the condition pages connected to this study.